Ceredex Value Advisors LLC Has $101.07 Million Stock Holdings in Revvity, Inc. (NYSE:RVTY)

Ceredex Value Advisors LLC reduced its holdings in Revvity, Inc. (NYSE:RVTY - Free Report) by 27.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 791,170 shares of the company's stock after selling 303,768 shares during the quarter. Revvity makes up about 2.0% of Ceredex Value Advisors LLC's portfolio, making the stock its 4th largest holding. Ceredex Value Advisors LLC owned about 0.64% of Revvity worth $101,072,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. EdgePoint Investment Group Inc. bought a new position in shares of Revvity in the 2nd quarter worth $209,221,000. Jane Street Group LLC boosted its holdings in Revvity by 516.4% in the 1st quarter. Jane Street Group LLC now owns 453,343 shares of the company's stock worth $47,601,000 after buying an additional 379,802 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Revvity by 18.5% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,126,271 shares of the company's stock valued at $223,258,000 after buying an additional 332,632 shares in the last quarter. Janus Henderson Group PLC grew its stake in Revvity by 3.9% during the first quarter. Janus Henderson Group PLC now owns 5,664,528 shares of the company's stock valued at $594,769,000 after acquiring an additional 210,100 shares in the last quarter. Finally, Coronation Fund Managers Ltd. increased its holdings in shares of Revvity by 261.3% in the first quarter. Coronation Fund Managers Ltd. now owns 253,722 shares of the company's stock worth $26,641,000 after purchasing an additional 183,490 shares during the period. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Stock Performance

Shares of RVTY stock traded up $2.45 during trading hours on Friday, reaching $121.04. The company had a trading volume of 1,474,334 shares, compared to its average volume of 818,094. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.98 and a current ratio of 2.27. Revvity, Inc. has a one year low of $82.17 and a one year high of $128.15. The firm has a market cap of $14.93 billion, a PE ratio of 87.71, a price-to-earnings-growth ratio of 3.31 and a beta of 1.05. The business has a fifty day moving average price of $121.39 and a 200-day moving average price of $114.02.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be paid a $0.07 dividend. The ex-dividend date is Friday, January 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.23%. Revvity's dividend payout ratio (DPR) is currently 20.29%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RVTY shares. TD Cowen raised their price target on Revvity from $130.00 to $141.00 and gave the company a "buy" rating in a research report on Tuesday, July 30th. Bank of America upped their price target on Revvity from $118.00 to $127.00 and gave the company a "neutral" rating in a research report on Tuesday, July 30th. Barclays raised shares of Revvity from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $125.00 to $140.00 in a research report on Tuesday, October 15th. Wells Fargo & Company initiated coverage on Revvity in a research report on Tuesday, August 27th. They set an "equal weight" rating and a $130.00 price target on the stock. Finally, Citigroup boosted their price objective on shares of Revvity from $135.00 to $145.00 and gave the stock a "buy" rating in a research note on Tuesday, July 30th. Seven analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $128.79.

Insider Buying and Selling at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 2,153 shares of the business's stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $122.09, for a total transaction of $262,859.77. Following the completion of the sale, the insider now owns 23,960 shares of the company's stock, valued at approximately $2,925,276.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Tajinder S. Vohra sold 2,154 shares of the company's stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total transaction of $262,206.42. Following the completion of the transaction, the insider now owns 19,652 shares in the company, valued at approximately $2,392,237.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Tajinder S. Vohra sold 2,153 shares of the firm's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $122.09, for a total value of $262,859.77. Following the transaction, the insider now owns 23,960 shares of the company's stock, valued at approximately $2,925,276.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,807 shares of company stock worth $937,576 in the last three months. 0.60% of the stock is currently owned by company insiders.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.